Amicus Therapeutics, Inc. (FOLD)Healthcare | Biotechnology | Princeton, United States | NasdaqGM
14.46 USD
+0.01
(0.069%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 14.45 -0.01 (-0.010%) ⇩ (April 17, 2026, 5:24 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 2:55 p.m. EDT
FOLD is currently trading near its 52-week high, with recent price action showing consolidation. The stock has a high beta, which indicates it's more volatile than the market average, and it's currently in a net loss position. While there are positive news headlines and analyst upgrades, the stock's fundamentals are weak, with negative profit margins and a high debt-to-equity ratio. The lack of dividend payouts and the low short-term price forecast make it a risky investment for short-term traders. Long-term investors might consider it if they are willing to take on the risk, but the overall risk profile is high, and the stock's fundamentals are not strong enough to justify a long-term hold. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.005946 |
| AutoETS | 0.005946 |
| AutoTheta | 0.005946 |
| MSTL | 0.011266 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 19.48 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.240 |
| Excess Kurtosis | -1.23 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 161.304 |
| Revenue per Share | 2.057 |
| Market Cap | 4,540,450,304 |
| Forward P/E | 17.66 |
| Beta | 0.48 |
| Profit Margins | -4.28% |
| Website | https://amicusrx.com |
As of April 11, 2026, 2:55 p.m. EDT: Options speculators are showing mixed signals. The calls and puts data indicate that there's significant positioning around strikes below the current price, suggesting potential for downward pressure. However, there are also calls with high open interest and volume, which could indicate bullish sentiment. The overall low implied volatility suggests that traders are not expecting large price swings in the near term, but the presence of puts with high open interest might indicate caution or hedging against a potential decline.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.1535022 |
| Address1 | 47 Hulfish Street |
| All Time High | 25.39 |
| All Time Low | 1.77 |
| Ask | 16.49 |
| Ask Size | 1 |
| Audit Risk | 4 |
| Average Daily Volume10 Day | 2,923,420 |
| Average Daily Volume3 Month | 4,691,263 |
| Average Volume | 4,691,263 |
| Average Volume10Days | 2,923,420 |
| Beta | 0.481 |
| Bid | 12.42 |
| Bid Size | 1 |
| Board Risk | 3 |
| Book Value | 0.882 |
| City | Princeton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 2 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 14.46 |
| Current Ratio | 2.843 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 14.46 |
| Day Low | 14.45 |
| Debt To Equity | 161.304 |
| Display Name | Amicus Therapeutics |
| Earnings Call Timestamp End | 1,762,263,000 |
| Earnings Call Timestamp Start | 1,762,263,000 |
| Earnings Growth | -0.955 |
| Earnings Quarterly Growth | -0.885 |
| Earnings Timestamp | 1,771,621,200 |
| Earnings Timestamp End | 1,778,184,000 |
| Earnings Timestamp Start | 1,778,184,000 |
| Ebitda | 41,951,000 |
| Ebitda Margins | 0.066149995 |
| Enterprise To Ebitda | 111.78 |
| Enterprise To Revenue | 7.394 |
| Enterprise Value | 4,689,277,440 |
| Eps Current Year | 0.07255 |
| Eps Forward | 0.81891 |
| Eps Trailing Twelve Months | -0.09 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 609 662 2001 |
| Fifty Day Average | 14.3792 |
| Fifty Day Average Change | 0.08080006 |
| Fifty Day Average Change Percent | 0.0056192316 |
| Fifty Two Week Change Percent | 115.35022 |
| Fifty Two Week High | 14.48 |
| Fifty Two Week High Change | -0.019999504 |
| Fifty Two Week High Change Percent | -0.0013811813 |
| Fifty Two Week Low | 5.51 |
| Fifty Two Week Low Change | 8.95 |
| Fifty Two Week Low Change Percent | 1.6243193 |
| Fifty Two Week Range | 5.51 - 14.48 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,180,618,200,000 |
| Float Shares | 311,435,326 |
| Forward Eps | 0.81891 |
| Forward P E | 17.657618 |
| Free Cashflow | 47,844,500 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 511 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.88501 |
| Gross Profits | 561,281,024 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00686 |
| Held Percent Institutions | 1.04178 |
| Implied Shares Outstanding | 314,000,712 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. |
| Long Name | Amicus Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 4,540,450,304 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_7009878 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -27,110,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,540,450,295 |
| Number Of Analyst Opinions | 5 |
| Open | 14.45 |
| Operating Cashflow | 33,145,000 |
| Operating Margins | 0.0861 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 609 662 2000 |
| Post Market Change | -0.010000229 |
| Post Market Change Percent | -0.069157876 |
| Post Market Price | 14.45 |
| Post Market Time | 1,776,461,050 |
| Previous Close | 14.45 |
| Price Eps Current Year | 199.31082 |
| Price Hint | 2 |
| Price To Book | 16.394558 |
| Price To Sales Trailing12 Months | 7.1592226 |
| Profit Margins | -0.04275 |
| Quick Ratio | 1.719 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0100002 |
| Regular Market Change Percent | 0.0692057 |
| Regular Market Day High | 14.46 |
| Regular Market Day Low | 14.45 |
| Regular Market Day Range | 14.45 - 14.46 |
| Regular Market Open | 14.45 |
| Regular Market Previous Close | 14.45 |
| Regular Market Price | 14.46 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 2,159,569 |
| Return On Assets | 0.02485 |
| Return On Equity | -0.11578 |
| Revenue Growth | 0.237 |
| Revenue Per Share | 2.057 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 314,000,712 |
| Shares Percent Shares Out | 0.0672 |
| Shares Short | 21,099,073 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 18,983,275 |
| Short Name | Amicus Therapeutics, Inc. |
| Short Percent Of Float | 0.0677 |
| Short Ratio | 5.58 |
| Source Interval | 15 |
| State | NJ |
| Symbol | FOLD |
| Target High Price | 14.5 |
| Target Low Price | 14.5 |
| Target Mean Price | 14.5 |
| Target Median Price | 14.5 |
| Total Cash | 293,536,000 |
| Total Cash Per Share | 0.935 |
| Total Debt | 442,363,008 |
| Total Revenue | 634,209,984 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.09 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.58825 |
| Two Hundred Day Average Change | 3.8717499 |
| Two Hundred Day Average Change Percent | 0.36566475 |
| Type Disp | Equity |
| Volume | 2,159,569 |
| Website | https://amicusrx.com |
| Zip | 8,542 |